MAGI - MAGI Regional Clinical Trial Agreement Requirements

MAGI Regional Clinical Trial Agreement Requirements

Please send us corrections, additions and deletions.

Display by:

Section:

Australia
Requirement:

CTA with institution. Principal Investigator sometimes signs.

Source:

Anonymous

Australia
Requirement:

Separate agreement with site/hospital/institution. Separate agreement with pharmacy, sometimes, even if in hospital.

Source:

Anonymous

Austria
Requirement:

CTA with institution. No separate investigator or pharmacy agreement required.

Source:

Anonymous

Belgium
Requirement:

Multiparty CTA. Institution signs. Principal Investigator signs. Separate pharmacy agreement?

Source:

Anonymous

Bulgaria
Requirement:

Multiparty CTA. Institution signs. Principal Investigator signs.

Source:

Anonymous

Bulgaria
Requirement:

Separate agreement with site/hospital/institution. Separate agreement with PI. Separate agreement with pharmacy, if different facility. No separate agreement with laboratory, if use hospital lab.

Source:

Anonymous

Czech Republic
Requirement:

CTA with institution. Investigators ("ResTrial") wanted separate agreement confidential from institution.

Source:

Anonymous

Denmark
Requirement:

CTA with institution. No separate pharmacy agreement required.

Source:

Anonymous

France
Requirement:

Single CTA. Institution signs. Principal Investigator signs.

Source:

Anonymous

France
Requirement:

Separate agreement with site/hospital/institution. Separate agreement with PI. Separate agreement with pharmacy, sometimes, if only drug storage and distribution required of if drug destruction required. No separate agreement with laboratory, if use hospital lab. Separate agreement with lead PI in France.

Source:

Anonymous

Page 1 of 5 with results 1-10 of 42. First Previous Next Last